Outcome after cavo-tricuspid isthmus ablation in patients with recurrent atrial fibrillation and drug-related typical atrial flutter.
This study evaluates the long-term clinical outcome of 56 consecutive patients affected by atrial fibrillation and drug-related typical atrial flutter who underwent cavo-tricuspid isthmus radiofrequency ablation. Symptomatic arrhythmic events recurred after ablation in 64% of the patients during follow-up of 19 +/- 9 months. Even in those who had recurrences, there was a substantial reduction in the incidence of episodes, quality of life was improved, and hospitalizations decreased.
Unità Operativa di Cardiologia Interventistica, Dipartimento di Cardiologia, Azienda Ospedaliera S. Maria Nuova, V. Risorgimento 80, Reggio Emilia, Italy. bottoni.nicola@asmn.re.it
Nicola
N
Bottoni
Paolo
P
Donateo
Fabio
F
Quartieri
Corrado
C
Tomasi
Daniele
D
Oddone
Gino
G
Lolli
Carlo
C
Menozzi
Michele
M
Brignole
D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy*; D001282:Atrial Flutter / Q000139:chemically induced* / Q000601:surgery*; D017115:Catheter Ablation / Q000379:methods*; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010359:Patient Readmission / Q000706:statistics & numerical data; D011183:Postoperative Complications / Q000209:etiology*; D011788:Quality of Life; D012008:Recurrence; D014261:Tricuspid Valve / Q000601:surgery*; D014683:Vena Cava, Superior / Q000601:surgery*
D000889:Anti-Arrhythmia Agents